2-[6-fluoro-1-[(3R,5S)-5-(fluoromethyl)-1-(4-hydroxyphenyl)sulfonylpyrrolidin-3-yl]indazol-3-yl]acetic acid
C20H19F2N3O5S — CID 130305469
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[6-fluoro-1-[(3R,5S)-5-(fluoromethyl)-1-(4-hydroxyphenyl)sulfonylpyrrolidin-3-yl]indazol-3-yl]acetic acid
2-[6-fluoro-1-[(3R,5S)-5-(fluoromethyl)-1-(4-hydroxyphenyl)sulfonylpyrrolidin-3-yl]indazol-3-yl]acetic acid (PubChem CID 130305469) has the molecular formula C20H19F2N3O5S and a molecular weight of 451.45 g/mol. Its IUPAC name is 2-[6-fluoro-1-[(3R,5S)-5-(fluoromethyl)-1-(4-hydroxyphenyl)sulfonylpyrrolidin-3-yl]indazol-3-yl]acetic acid.
Molecular Properties
| Compound Name | 2-[6-fluoro-1-[(3R,5S)-5-(fluoromethyl)-1-(4-hydroxyphenyl)sulfonylpyrrolidin-3-yl]indazol-3-yl]acetic acid |
|---|---|
| PubChem CID | 130305469 |
| Molecular Formula | C20H19F2N3O5S |
| Molecular Weight | 451.45 g/mol |
| Exact Mass | 451.10 |
| IUPAC Name | 2-[6-fluoro-1-[(3R,5S)-5-(fluoromethyl)-1-(4-hydroxyphenyl)sulfonylpyrrolidin-3-yl]indazol-3-yl]acetic acid |
| SMILES | O=C(O)Cc1nn([C@@H]2C[C@@H](CF)N(S(=O)(=O)c3ccc(O)cc3)C2)c2cc(F)ccc12 |
| InChI | InChI=1S/C20H19F2N3O5S/c21-10-13-8-14(11-24(13)31(29,30)16-4-2-15(26)3-5-16)25-19-7-12(22)1-6-17(19)18(23-25)9-20(27)28/h1-7,13-14,26H,8-11H2,(H,27,28)/t13-,14+/m0/s1 |
| InChIKey | MMKWZDOXMJBKCL-UONOGXRCSA-N |
| XLogP | 2.48 |
| TPSA | 112.73 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 451.45 |
| LogP ≤ 5 | 2.48 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 130305469 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.